Study S001333

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07104383
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 1100
Start: 2025-06-23
Primary completion: 2027-07-01
Lead sponsor: Viking Therapeutics, Inc.
Conditions: Weight Loss
Interventions: DRUG:VK2735
Results posted: FALSE

Registered primary outcomes

Percent change in body weight from baseline to Week 78 in body weight [78 Weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0056047	Pre-registered mechanistic prediction: VK2735 in VANQUISH-2 (NCT07104383) Natalija Karpichina, Zenodo (CERN European Organization for Nuclear Research)	2026	Nonrandomized study	DOI	cites ClinicalTrials.gov:NCT07104383